Derivation and Characterization of Isogenic OPA1 Mutant and Control Human Pluripotent Stem Cell Lines
Cells · 2025
DOI: 10.3390/cells14020137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Katherine A Pohl und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: GTP Phosphohydrolases, Mutation, Optic Atrophy, Autosomal Dominant, Pluripotent Stem Cells. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH HHS, National Institute of Health (NIH).
Abstract (Originalsprache)
Dominant optic atrophy (DOA) is the most commonly inherited optic neuropathy. The majority of DOA is caused by mutations in the OPA1 gene, which encodes a dynamin-related GTPase located to the mitochondrion. OPA1 has been shown to regulate mitochondrial dynamics and promote fusion. Within the mitochondrion, proteolytically processed OPA1 proteins form complexes to maintain membrane integrity and the respiratory chain complexity. Although OPA1 is broadly expressed, human OPA1 mutations predominantly affect retinal ganglion cells (RGCs) that are responsible for transmitting visual information from the retina to the brain. Due to the scarcity of human RGCs, DOA has not been studied in depth using the disease affected neurons. To enable studies of DOA using stem-cell-derived human RGCs, we performed CRISPR-Cas9 gene editing to generate OPA1 mutant pluripotent stem cell (PSC) lines with corresponding isogenic controls. CRISPR-Cas9 gene editing yielded both OPA1 homozygous and heterozygous mutant ESC lines from a parental control ESC line. In addition, CRISPR-mediated homology-directed repair (HDR) successfully corrected the OPA1 mutation in a DOA patient’s iPSCs. In comparison to the isogenic controls, the heterozygous mutant PSCs expressed the same OPA1 protein isoforms but at reduced levels; whereas the homozygous mutant PSCs showed a loss of OPA1 protein and altered mitochondrial morphology. Furthermore, OPA1 mutant PSCs exhibited reduced rates of oxygen consumption and ATP production associated with mitochondria. These isogenic PSC lines will be valuable tools for establishing OPA1-DOA disease models in vitro and developing treatments for mitochondrial deficiency associated neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
- Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA.
- Department of Molecular and Medical Pharmacology, Davide Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
- Doheny Eye Center, Department of Ophthalmology, University of California, Los Angeles, CA 91103, USA.
ORCID-Profile: Xian-Jie Yang
Förderung
- NEI NIH HHS
- NIH HHS
- National Institute of Health (NIH)
- California Institute of Regenerative Medicine (CIRM)
- Research to Prevent Blindness to the Department of Ophthalmology at University of California, Los Angeles
Zitieren
APA
Pohl, K. A., Zhang, X., Ji, J. J., Stiles, L., Sadun, A. A., & Yang, X. J. (2025). Derivation and Characterization of Isogenic OPA1 Mutant and Control Human Pluripotent Stem Cell Lines. Cells. https://doi.org/10.3390/cells14020137
Vancouver
Pohl KA, Zhang X, Ji JJ, Stiles L, Sadun AA, Yang XJ. Derivation and Characterization of Isogenic OPA1 Mutant and Control Human Pluripotent Stem Cell Lines. Cells. 2025. doi:10.3390/cells14020137
BibTeX
@article{Pohl2025,
author = {Pohl, Katherine A and Zhang, Xiangmei and Ji, Johnny Jeonghyun and Stiles, Linsey and Sadun, Alfredo A and Yang, Xian-Jie},
title = {Derivation and Characterization of Isogenic OPA1 Mutant and Control Human Pluripotent Stem Cell Lines},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14020137}
}
EUVIMED